PPIs associated with COPD and asthma exacerbations
A recent Belgian study found that the use of proton pump inhibitors (PPIs) is associated with increased exacerbations of COPD and asthma (which they refer to as chronic obstructive airway diseases, COADs) in a dose-response way: see copd inc with PPIs Chest2026 in dropbox, or DOI: https://doi.org/10.1016/j.chest.2026.01.002 Details : -- 932,135 patients (with a total of 1,084,446 person-years of follow-up) were identified using the Belgian nationwide claims-based data of adult patients receiving long-term medication for COADs (ie, having at least two dispensings of medication for obstructive lung diseases) between 2017 and 2022 -- patients on histamine type 2 receptor antagonists (H2RAs) were excluded (at that time there was a carcinogen impurity found in ranitidine, the most prescribed H2 blocker, that was taken off the market), -- 416,087 patients (44.6%) were also receiving PPIs: -- mean age 61, 54% female, 29% low socioeconomic status (assessed by their medical cover...